Oxford Finance, a finance firm providing senior debt to life sciences and healthcare services companies, closed a $122 million senior credit facility for Tarrytown, a closed-door, long-term care pharmacy specializing in serving individuals with intellectual and developmental disabilities.
Oxford Finance, a finance firm providing senior debt to healthcare services and life sciences companies, closed a $107 million senior credit facility to Specialty Dental Brands, a dental services organization focused on pediatric dentistry, orthodontics and oral surgery.
Oxford Finance delivered a secured credit facility totaling $30 million to Greenbrook TMS, a U.S. provider of transcranial magnetic stimulation therapy.
Oxford Finance delivered a credit facility to lateral flow diagnostics developer DCN Dx while also arranging an equity investment for the company by Martis Capital, a private equity firm focused on the healthcare industry.
Oxford Finance, a finance firm providing senior debt to healthcare services and life sciences companies, provided a $7.4 million senior credit facility and revolving line of credit to REACH, a provider of short- and long-term skilled care options.
Oxford Finance, a finance firm that provides senior debt to healthcare services and life sciences companies, provided a $44.6 million senior credit facility and revolving line of credit to MDA Capital Group, a consulting services provider to the nursing home industry.
Oxford Finance provided a $60 million senior secured term loan for RxSight, a privately-held MedTech company that commercialized an FDA-approved adjustable intraocular lens that is customized after cataract surgery.
Specialty finance firm Oxford Finance closed a senior credit facility and revolving line of credit to ThermoTek, a designer and manufacturer of temperature management devices. The proceeds will partially fund the acquisition of ThermoTek by Havencrest Capital Management, a Dallas-based healthcare private equity firm.
Oxford Finance closed a $15 million senior secured term loan with Vedanta Biosciences, a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia.
Selecta Biosciences entered into a debt financing facility for up to $35 million with Oxford Finance and Silicon Valley Bank. Selecta will use the financing to retire $12.6 million of existing debt, to advance its ImmTOR pipeline and for business development activities.